SCHEMBL3198679

SCHEMBL3198679

COc1ccc2c(c1)C=C(C(=O)O)CO2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.64
SHMT2 P34897 1/20 0.64
NR1H4 Q96RI1 2/20 0.62
MAPT P10636 2/20 0.59
MEN1 O00255 1/20 0.59
HSP90AA1 P07900 1/20 0.59
GAA P10253 1/20 0.59
HTT P42858 1/20 0.59
KMT2A Q03164 1/20 0.59
MTNR1A P48039 2/20 0.57
ALOX5 P09917 4/20 0.56
ALDH1A1 P00352 1/20 0.56
TP53 P04637 1/20 0.55
CA12 O43570 2/20 0.53
CA9 Q16790 2/20 0.53
CA2 P00918 1/20 0.53
NPC1 O15118 1/20 0.51
NFKB1 P19838 1/20 0.51
RAB9A P51151 1/20 0.51
NFKB2 Q00653 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL432850 0.88 ALOX5 (0.71) MAOBSHMT2NR1H4MAPTMEN1
SCHEMBL9058391 0.88 MAOB (0.64) MAOBSHMT2NR1H4MAPTMEN1
SCHEMBL5794944 0.87 MAPT (0.64) MAOBSHMT2NR1H4MAPTMEN1
SCHEMBL27934719 0.86 TP53 (0.52) MAOBSHMT2NR1H4MAPTMEN1
SCHEMBL6756877 0.86 MTNR1A (0.52) MAOBSHMT2NR1H4MAPTMEN1
SCHEMBL29260616 0.85 ALOX5 (0.57) MAOBSHMT2NR1H4MAPTMEN1
SCHEMBL1208429 0.82 PTGS1 (0.56) MAOBSHMT2NR1H4MAPTMEN1
SCHEMBL20839505 0.80 MEN1 (0.48) MAOBSHMT2NR1H4MAPTMEN1
SCHEMBL415706 0.80 CA12 (0.59) MAOBSHMT2NR1H4MAPTMEN1
SCHEMBL7199599 0.80 PTGS1 (0.47) MAOBSHMT2NR1H4MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029682-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME PIERRE FABRE MEDICAMENT (FR) 2010-02-04 US claimed
EP-2057138-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME Pierre Fabre Medicament (FR) 2009-05-13 EP claimed
WO-2008009741-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME PIERRE FABRE MEDICAMENT (FR) 2008-01-24 WO claimed
EP-4703358-A1 BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF China Pharmaceutical University (CN) 2026-03-04 EP disclosed
WO-2025092775-A1 PHTHALAZINONE GSPT1 PROTEIN DEGRADING AGENT AND USE THEREOF 中国药科大学 2025-05-08 WO disclosed
CN-119912437-A Phthalazinone GSPT protein degradation agent and application thereof 中国药科大学 2025-05-02 CN disclosed
WO-2024222918-A1 BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF 中国药科大学 2024-10-31 WO disclosed
US-20160194299-A1 COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH 2016-07-07 US disclosed
US-20160194299-A1 COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH 2016-07-07 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
WO-2014190199-A1 COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2014-11-27 WO disclosed
US-20100029682-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME PIERRE FABRE MEDICAMENT (FR) 2010-02-04 US disclosed
EP-2057138-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME Pierre Fabre Medicament (FR) 2009-05-13 EP disclosed
WO-2008009741-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME PIERRE FABRE MEDICAMENT (FR) 2008-01-24 WO disclosed
WO-2006040646-A1 BENZIMIDAZOLE OR INDOLE AMIDES AS INHIBITORS OF PIN1 PFIZER, INC. (US) 2006-04-20 WO disclosed
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029682-A1 NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME DRD3, CHRNA3, CHRM3 MAOB 264/4885SHMT2 563/4885NR1H4 1079/4885
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 MAOB 1631/4885SHMT2 4604/4885NR1H4 3043/4885
US-20160194299-A1 COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS FNTB, PGLS, EP300 MAOB 651/4885SHMT2 1026/4885NR1H4 2147/4885
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 MAOB 126/4885SHMT2 449/4885NR1H4 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.